MedTrace Logo

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

NCT03223779 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-03-12

No results posted yet for this study

Summary

This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer.

The interventions involved in this study are:

* Trifluridine (TAS-102)
* Radiation Therapy

Conditions

Interventions

DRUG

TAS-102

Trifluridine stops DNA replication which may prevent the cancer cells from growing

RADIATION

Photon SBRT

SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells

Sponsors & Collaborators

  • Taiho Oncology, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Jennifer Y. Wo, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2025-02-03
Completion
2025-10-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03223779 on ClinicalTrials.gov